Kidney cancer study reveals Real-World use of top drug combos

This completed study looked at 327 adults with advanced kidney cancer who received one of two drug combinations (nivolumab+ipilimumab or pembrolizumab+lenvatinib) in real-world U.S. clinics. Researchers collected data on patient characteristics, treatment patterns, and outcomes from medical records. The goal was to describe how these approved therapies are actually used outside of clinical trials, not to test new treatments.